Cargando…
Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome
Patients with CYLD cutaneous syndrome (CCS; syn. Brooke-Spiegler syndrome) carry germline mutations in the tumor suppressor CYLD and develop multiple skin tumors with diverse histophenotypes. Here, we comprehensively profile the genomic landscape of 42 benign and malignant tumors across 13 individua...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797807/ https://www.ncbi.nlm.nih.gov/pubmed/31624251 http://dx.doi.org/10.1038/s41467-019-12746-w |
_version_ | 1783459915111596032 |
---|---|
author | Davies, Helen R. Hodgson, Kirsty Schwalbe, Edward Coxhead, Jonathan Sinclair, Naomi Zou, Xueqing Cockell, Simon Husain, Akhtar Nik-Zainal, Serena Rajan, Neil |
author_facet | Davies, Helen R. Hodgson, Kirsty Schwalbe, Edward Coxhead, Jonathan Sinclair, Naomi Zou, Xueqing Cockell, Simon Husain, Akhtar Nik-Zainal, Serena Rajan, Neil |
author_sort | Davies, Helen R. |
collection | PubMed |
description | Patients with CYLD cutaneous syndrome (CCS; syn. Brooke-Spiegler syndrome) carry germline mutations in the tumor suppressor CYLD and develop multiple skin tumors with diverse histophenotypes. Here, we comprehensively profile the genomic landscape of 42 benign and malignant tumors across 13 individuals from four multigenerational families and discover recurrent mutations in epigenetic modifiers DNMT3A and BCOR in 29% of benign tumors. Multi-level and microdissected sampling strikingly reveal that many clones with different DNMT3A mutations exist in these benign tumors, suggesting that intra-tumor heterogeneity is common. Integrated genomic, methylation and transcriptomic profiling in selected tumors suggest that isoform-specific DNMT3A2 mutations are associated with dysregulated methylation. Phylogenetic and mutational signature analyses confirm cylindroma pulmonary metastases from primary skin tumors. These findings contribute to existing paradigms of cutaneous tumorigenesis and metastasis. |
format | Online Article Text |
id | pubmed-6797807 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-67978072019-10-21 Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome Davies, Helen R. Hodgson, Kirsty Schwalbe, Edward Coxhead, Jonathan Sinclair, Naomi Zou, Xueqing Cockell, Simon Husain, Akhtar Nik-Zainal, Serena Rajan, Neil Nat Commun Article Patients with CYLD cutaneous syndrome (CCS; syn. Brooke-Spiegler syndrome) carry germline mutations in the tumor suppressor CYLD and develop multiple skin tumors with diverse histophenotypes. Here, we comprehensively profile the genomic landscape of 42 benign and malignant tumors across 13 individuals from four multigenerational families and discover recurrent mutations in epigenetic modifiers DNMT3A and BCOR in 29% of benign tumors. Multi-level and microdissected sampling strikingly reveal that many clones with different DNMT3A mutations exist in these benign tumors, suggesting that intra-tumor heterogeneity is common. Integrated genomic, methylation and transcriptomic profiling in selected tumors suggest that isoform-specific DNMT3A2 mutations are associated with dysregulated methylation. Phylogenetic and mutational signature analyses confirm cylindroma pulmonary metastases from primary skin tumors. These findings contribute to existing paradigms of cutaneous tumorigenesis and metastasis. Nature Publishing Group UK 2019-10-17 /pmc/articles/PMC6797807/ /pubmed/31624251 http://dx.doi.org/10.1038/s41467-019-12746-w Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Davies, Helen R. Hodgson, Kirsty Schwalbe, Edward Coxhead, Jonathan Sinclair, Naomi Zou, Xueqing Cockell, Simon Husain, Akhtar Nik-Zainal, Serena Rajan, Neil Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome |
title | Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome |
title_full | Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome |
title_fullStr | Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome |
title_full_unstemmed | Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome |
title_short | Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome |
title_sort | epigenetic modifiers dnmt3a and bcor are recurrently mutated in cyld cutaneous syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797807/ https://www.ncbi.nlm.nih.gov/pubmed/31624251 http://dx.doi.org/10.1038/s41467-019-12746-w |
work_keys_str_mv | AT davieshelenr epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome AT hodgsonkirsty epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome AT schwalbeedward epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome AT coxheadjonathan epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome AT sinclairnaomi epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome AT zouxueqing epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome AT cockellsimon epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome AT husainakhtar epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome AT nikzainalserena epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome AT rajanneil epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome |